消化道感染筛查综合诊断套餐

一、套餐名称

中文： 消化道感染筛查综合诊断套餐
英文： Comprehensive Diagnostic Screening for Digestive Tract Infections

二、特色项目

1. C-13 呼气试验
C-13 Urea Breath Test

2. 幽门螺杆菌培养及药敏试验
Helicobacter pylori Culture and Antimicrobial Susceptibility Test

3. 肠道菌群微生态检测
Gut Microbiome Ecological Analysis

4. 病原体宏基因测序（mNGS）
Metagenomic Next-Generation Sequencing (mNGS) for Pathogen Detection

三、套餐临床价值

本套餐通过无创与精准检测技术相结合，全面评估消化道感染性病因：

This comprehensive panel combines non-invasive and precise technologies to thoroughly evaluate infectious etiologies of the digestive tract:

· C-13呼气试验：无痛、无创，快速诊断当前是否感染幽门螺杆菌，是胃溃疡、慢性胃炎评估的首选方法。

C-13 Urea Breath Test – Painless and non-invasive, it provides rapid detection of active H. pylori infection, serving as the preferred tool for assessing risks of gastric ulcers and chronic gastritis.

· 幽门螺杆菌培养及药敏试验：明确菌株对抗生素的敏感性，指导个体化根除治疗，避免经验用药导致的耐药失败。

H. pylori Culture and Susceptibility Testing – Identifies antibiotic resistance profiles of the isolated strain, enabling tailored eradication therapy and reducing failure rates associated with empirical treatment.

· 肠道菌群微生态检测：分析肠道有益菌与致病菌平衡，评估肠道屏障功能及炎症水平，为腹泻、IBD等疾病提供微生态干预依据。

Gut Microbiome Ecological Analysis – Assesses the balance between beneficial and pathogenic gut flora, evaluates mucosal barrier function and inflammatory markers, offering evidence for microbiome-targeted interventions in conditions like diarrhea and IBD.

· 病原体宏基因测序（mNGS）：一次性无偏性检测粪便或消化道标本中的全部细菌、病毒、真菌及寄生虫DNA/RNA，尤其适用于疑难、重症或混合感染病例，实现病因精准锁定。

Metagenomic Next-Generation Sequencing (mNGS) – Unbiased, one-time detection of all bacterial, viral, fungal, and parasitic DNA/RNA in stool or digestive specimens. Particularly valuable for complex, severe, or polymicrobial infections, it ensures precise etiological identification.

综合价值：从常规筛查到精准溯源，覆盖“有无感染 → 何种病原 → 如何用药 → 微生态修复”全链条，显著提升消化道感染的诊断效率与治愈率，降低抗生素滥用风险。

Overall Clinical Value: Spanning from routine screening to precise etiological tracking, this package covers the entire diagnostic cascade – infection status → pathogen identity → drug selection → microbiome restoration. It significantly improves diagnostic yield and cure rates while minimizing inappropriate antibiotic use.

阿尔兹海默症综合辅助诊断套餐

一、套餐名称

中文： 阿尔兹海默症综合辅助诊断套餐
英文： Comprehensive Assistive Diagnostic Panel for Alzheimer’s Disease

二、特色项目

1. 载脂蛋白 E（APOE）基因基因多态性检测

Apolipoprotein E (APOE) Gene Polymorphism Analysis

2. 血浆β-淀粉样蛋白（Aβ42、Aβ40、Aβ42/Aβ40）检测

Plasma Amyloid-β (Aβ42, Aβ40, and Aβ42/Aβ40 Ratio) Assay

3. 血浆磷酸化 Tau 蛋白（p-Tau 217）检测

Plasma Phosphorylated Tau (p-Tau 217) Detection

三、套餐临床价值

本套餐从“遗传风险预警 → 早期病理识别 → 疾病鉴别”三个维度，为阿尔兹海默症提供系统化的辅助诊断依据：

This panel provides a systematic auxiliary diagnostic framework for Alzheimer‘s disease across three dimensions: genetic risk warning → early pathological recognition → disease differentiation:

· 遗传风险评估：APOE 基因多态性检测可于症状出现前明确终身患病风险层级，帮助筛选高危人群，指导定期随访与生活方式干预。

Genetic Risk Assessment – APOE genotyping identifies lifetime risk stratification before symptom onset, helping to screen high-risk individuals and guide regular surveillance and lifestyle interventions.

· 早期病理识别：血浆 Aβ42/Aβ40 比值异常可在认知功能明显下降前数年提示脑内淀粉样蛋白阳性沉积，将诊断窗口大幅前移。

Early Pathological Recognition – Abnormal plasma Aβ42/Aβ40 ratio can signal positive cerebral amyloid deposition years before measurable cognitive decline, significantly advancing the diagnostic window.

· 精准鉴别诊断：p-Tau 217 联合 Aβ 标志物，可有效区分阿尔兹海默症与额颞叶痴呆、路易体痴呆、血管性痴呆等其他类型认知障碍，减少误诊。

Precise Differential Diagnosis – The combination of p-Tau 217 and Aβ markers effectively distinguishes Alzheimer’s disease from other types of cognitive impairment, including frontotemporal dementia, dementia with Lewy bodies, and vascular dementia, thereby reducing misdiagnosis.

综合价值：本套餐整合三项血液生物标志物，覆盖阿尔兹海默症从遗传风险评估、早期病理识别到痴呆鉴别的完整辅助诊断链路。检测无创、可重复，适用于认知正常人群的早期风险筛查、轻度认知障碍（MCI）患者的病因倾向判断，以及痴呆类型的鉴别，为临床决策提供客观量化依据。

This panel integrates three blood-based biomarkers to cover the full diagnostic cascade for Alzheimer’s disease — from genetic risk stratification and early pathological detection to differential diagnosis among dementias. It is non-invasive, repeatable, and suitable for screening asymptomatic individuals, evaluating MCI patients, and guiding clinical decisions with objective, quantifiable evidence.